| Quantity: | |
|---|---|
Lacosamide oral solution is a 10 mg/mL antiepileptic liquid used as monotherapy or add-on therapy for partial-onset seizures, and the formulation that reaches your market is usually decided by four things: the excipient system, the preservative efficacy data, the in-use shelf life claim, and whether the dosing device matches the label. None of these show up on a price quotation. All of them show up in a deficiency letter.
Lacosamide is a functionalized amino acid anticonvulsant supplied as the single (R)-enantiomer. The chemical name is (R)-2-acetamido-N-benzyl-3-methoxypropionamide, molecular formula C13H18N2O3, molecular weight 250.30, CAS number 175481-36-4. The drug substance is a white to light yellow powder, sparingly soluble in water at roughly 30 mg per mL at 25 degrees Celsius, slightly soluble in acetonitrile and ethanol.
The mechanism differs from classical sodium channel blockers. Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, which stabilizes hyperexcitable neuronal membranes and inhibits repetitive neuronal firing. It does not act primarily on the fast-inactivated channel state that carbamazepine and phenytoin target, and it has comparatively few pharmacokinetic interactions with other antiepileptic drugs.
Oral bioavailability is close to complete, and the terminal half-life is around 13 hours, which supports twice-daily dosing. The same molecule is also supplied as film-coated tablets and as a 10 mg/mL injection, and switching between oral and intravenous routes does not require re-titration.
Concentration: 10 mg lacosamide per mL
Bottle contents: 200 mL bottle contains 2,000 mg lacosamide; a 465 mL bottle contains 4,650 mg
Appearance: clear, colourless to yellow or yellow-brown liquid, strawberry flavoured, free from particulate matter
pH and viscosity: product specific, specify in the release specification rather than relying on the reference product
Preservative system: typically methylparaben, sometimes with propylparaben; confirm against your market's restriction list
Sweetener and vehicle: sorbitol solution, glycerin, macrogol, carmellose sodium, acesulfame potassium, sucralose or aspartame depending on the developer
Sodium content: roughly 1.3 mg per mL in reference-type formulations; declare it if your market requires sodium labelling
Dosage forms available for the same molecule: 10 mg/mL oral solution, 10 mg/mL injection, 50, 100, 150 and 200 mg film-coated tablets
Legal status: prescription only
Storage: below 30 degrees Celsius, do not refrigerate, do not freeze
Shelf life: three years unopened for the reference product; in-use period after first opening is product specific and must be supported by data
The oral solution is not a convenience line extension. It covers patients the tablet cannot serve.
Children under roughly 50 kg are dosed by body weight, starting at 1 mg per kg twice daily and titrating weekly by 1 mg per kg twice daily, with maintenance commonly reaching 4 to 6 mg per kg twice daily depending on weight band. A 10 mg/mL liquid lets a prescriber deliver 35 mg or 85 mg without splitting tablets, which is not possible with 50 mg and 100 mg strengths.
Patients with dysphagia, and patients on a nasogastric or gastrostomy tube, need a liquid. The solution can be administered through a feeding tube provided the tube is flushed with at least twice its dead-space volume afterwards, and it can be diluted in a glass of water before swallowing.
Status epilepticus and perioperative situations where oral intake stops temporarily are handled by the injection, but the oral solution is what allows early discharge and outpatient continuation at the same dose.
An oral solution has no dissolution profile to hide behind. The formulation is fully exposed, and the excipients become the regulatory discussion.
Sorbitol load. Reference-type formulations contain around 187 mg of sorbitol per mL. At a 20 mL dose that is close to 3.7 g of sorbitol, enough to cause osmotic diarrhoea in sensitive patients and a documented concern in hereditary fructose intolerance. Some markets require a specific warning; some require the sorbitol content to be declared quantitatively. Confirm the wording obligation before you print cartons.
Paraben preservatives. Methylparaben at around 2 mg per mL is common, sometimes with propylparaben. Parabens are restricted or under review in several jurisdictions, and patients with documented paraben sensitivity need a warning. If your target market is moving away from parabens, reformulating later means a new bioequivalence or at minimum a new stability programme, so decide before you file.
Sweetener profile. Acesulfame potassium appears in most versions; sucralose in some, aspartame in others. Aspartame carries a phenylketonuria warning and is rejected in a number of markets for that reason. Sucralose and acesulfame potassium have their own labelling thresholds in some countries.
Sodium content. About 1.3 mg per mL does not sound like much until a patient takes 20 mL twice daily for years. Markets with sodium declaration rules for medicines will expect the figure per maximum daily dose, not per mL.
Alcohol and glycols. Some flavour systems carry propylene glycol. Check the total glycol intake against the excipient guideline your authority applies to paediatric patients, since the solution is used in children from two or four years of age depending on the market.
Colour and flavour matching. The reference product is colourless to yellow-brown, and the colour shifts with storage. Buyers comparing a sample against the innovator sometimes reject a batch for a colour difference that is inside specification. Agree the colour range in writing at contract stage.
A liquid is judged on how it behaves after the bottle is opened, not only at release.
In-use period. The reference product specifies discarding within two months of first opening in some markets and six months in others, depending on the preservative efficacy and in-use stability data held. If you claim six months you need the data to defend it, including microbial challenge after repeated opening.
Dosing device. The pack normally includes a 10 mL oral syringe. If your kit uses a different device, or a measuring cup, the dose accuracy claim and the patient instructions both change. Regulators increasingly ask for the device to be specified in the dossier rather than treated as packaging.
Dilution and tube administration. Instructions for dilution in water and for flushing a feeding tube are part of the label. A generic that omits them creates a real-world dosing error risk in exactly the patients the liquid exists for.
Crystallisation and separation. Sorbitol solutions can crystallise at low temperature, and the label instruction not to refrigerate exists for that reason. Stability data should include a freeze-thaw or low-temperature excursion cycle if your market has cold supply chains.
Beyond assay and related substances, a solution dossier carries its own set of expectations.
Preservative efficacy testing per the applicable pharmacopoeial method, at release and at the end of shelf life.
Microbial limits and, where relevant, specified organism testing for a multi-dose aqueous product.
In-use stability covering the claimed period after first opening, with preservative content re-assayed at the end.
Elemental impurities per ICH Q3D and a nitrosamine risk assessment. The risk here is lower than for a tablet, but the statement is still expected.
Extractables and leachables from the bottle, closure and dosing device, particularly where the pack is PET rather than glass.
Stability data at long-term and accelerated conditions matched to your climatic zone, including colour and pH drift, which are the two parameters most likely to move in an aqueous formulation.
Batch certificate of analysis, GMP certificate with scope covering oral liquids, and CTD module 3 content including process validation for a non-sterile liquid line.
【To be confirmed before publication: whether Loncom holds a registration for lacosamide oral solution, the approved strength and pack size, manufacturing capability for non-sterile oral liquids, GMP certificate scope, and whether an in-use stability and preservative efficacy package is available to licensing partners. No claim should be published in this section until these points are verified.】
Lacosamide oral solution is not interchangeable with other sodium channel blockers on a milligram basis, and it does not replace the injection in status epilepticus. It carries a PR interval prolongation warning, so patients with second-degree AV block or on other PR-prolonging drugs need assessment before titration. Severe hepatic impairment is not a recommended population. Abrupt discontinuation increases seizure frequency, and withdrawal should be tapered over at least one week.
A liquid formulation is easy to copy and hard to get right. The difference is not in the assay, which any competent manufacturer can hit, but in the four years of in-use data behind a shelf-life claim that a prescriber never reads and a patient depends on.
Product Description
Indications
Lacosamide is an antiepileptic medication indicated for the treatment of partial-onset seizures in adults and adolescents (16 years and older) with epilepsy.
Dosage and Administration:The dosage of Lacosamide oral solution is individualized based on factors such as age, weight, and renal function. It is important to follow the prescribing healthcare provider's instructions and the information provided in the product packaging.
The oral solution can be taken with or without food, and it is usually measured using a calibrated oral syringe or another suitable measuring device for accurate dosing.
Storage:Lacosamide oral solution should be stored at room temperature, away from light and moisture. It is crucial to keep the container tightly closed when not in use. Be sure to check the expiration date before using the product.
Contraindications:Lacosamide oral solution is contraindicated in patients with a known hypersensitivity to lacosamide or any of the other ingredients in the formulation.
Warnings and Precautions:
Patients should be monitored for cardiac and neurological adverse reactions.
Lacosamide may cause dizziness or ataxia, so patients should be advised not to drive or operate machinery until they know how the medication affects them.
Side Effects
Common side effects may include dizziness, headache, and nausea. Serious side effects are rare but may include cardiovascular effects and psychiatric symptoms. Patients should seek medical attention if they experience any unusual or severe side effects.
Remember, this is a hypothetical product description, and specific details may vary based on the actual product available in the market. Always refer to the specific product information provided by the manufacturer or healthcare professional for accurate and up-to-date details on a particular Lacosamide oral solution product.
FAQ
What pack sizes are available? Standard 200 mL PET bottle; unit-dose cups (50 mg/5 mL, 100 mg/10 mL) can be quoted against MOQ.
Is this the same as Vimpat oral solution? Same active ingredient and strength; as a generic it is supported by bioequivalence data under the relevant ANDA/registration.
Can it be given by feeding tube? Only where the local label and clinical protocol allow — confirm against the approved label in your market.
Do you support registration? Yes — DMF/CEP, GMP evidence and CTD modules on request.
